Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma

HIROKI NISHIKAWA1, AKIRA ARIMOTO2, TOMOKO WAKASA3, RYUICHI KITA1, TORU KIMURA1 and YUKIO OSAKI1

Departments of 1Gastroenterology and Hepatology, 2Surgery and 3Pathology, Osaka Red Cross Hospital, Tennoji-ku, Osaka 543-0027, Japan

Received September 11, 2012; Accepted October 22, 2012

DOI: 10.3892/ijo.2012.1711

Abstract. The aim of the present study was to evaluate the influence of preoperative transcatheter arterial chemoembolization (TACE) on survival after surgical resection (SR) for hepatocellular carcinoma (HCC). Two hundred and thirty-five HCC patients who underwent SR with curative intent were analyzed. Overall survival (OS), recurrence-free survival (RFS) and complication rates were compared between the TACE (n=110) and control groups (n=125). Moreover, TACE subjects were classified into TACE responders (n=85) and TACE non-responders (n=25), according to the therapeutic efficacy of pretreatment TACE, and the factors contributing to OS and RFS after SR were analyzed using univariate and multivariate analyses. The 1-, 3- and 5-year OS rates were 87.4, 76.0 and 62.5%, respectively, in the TACE group and 94.9, 79.0 and 57.8%, respectively, in the control group (P=0.674). The corresponding RFS rates at 1, 3 and 5 years were 73.3, 48.9 and 33.2%, respectively, in the TACE group and 73.3, 29.4 and 16.3%, respectively, in the control group (P=0.062). No TACE-related serious adverse events (SAEs) were observed. There were no significant differences between the groups in terms of surgery-related SAEs (P=0.714), operation time (P=0.881), blood loss during surgery (P=0.334) and hospitalization period (P=0.447). Multivariate analyses identified TACE responder, TACE non-responder, total bilirubin ≥1 mg/dl, serum albumin ≥4 g/dl, pretreatment α-fetoprotein (AFP) level ≥100 ng/ml and microscopic vascular invasion as significant prognostic factors linked to OS. TACE non-responder, tumor number (multiple) and pretreatment AFP level ≥100 ng/ml were significant adverse prognostic factors linked to RFS. In conclusion, TACE is a safe procedure in patients with HCC, and the efficacy of TACE prior to surgery may be associated with clinical outcomes after SR.

Introduction

Hepatocellular carcinoma (HCC) is a major health problem worldwide, with an estimated incidence ranging between 500,000 and 1,000,000 new cases annually. It is the fifth most common cancer in the world and the third most common cause of cancer-related death (1,2). The prognosis of HCC is generally poor because of the high recurrence rate (1,3,4). Surgical resection (SR) remains the best curative treatment, but is only suitable in 9-27% of patients. The presence of significant background liver cirrhosis often precludes hepatic resection in patients with HCC. Recurrence in the liver remnant is also common in patients who have undergone radical hepatic resection (5).

Transcatheter arterial chemoembolization (TACE) is one of the available locoregional therapies for HCC. It involves injection of an embolizing agent into the hepatic artery to deprive the tumor of its major nutrient source via embolization of the nutrient artery, resulting in ischemic necrosis of the tumor (6-8). According to the current guidelines, TACE is generally performed in intermediate-stage HCC patients (9). However, TACE has also been performed as preoperative adjuvant chemotherapy in resectable HCC patients with the aim of improving survival (3,10,11).

The purpose of preoperative TACE is to reduce tumor volume, induce tumor necrosis and prevent cancer cell dissemination during the surgical procedure (3,10,11). To the best of our knowledge, four randomized controlled trials have assessed the efficacy of preoperative TACE in terms of survival (3,10,12,13). However, the results of these trials are difficult to compare because of differences in baseline clinical characteristics such as tumor size, cause of liver disease and chemotherapeutic agents used when performing TACE. Hence, the postoperative survival benefits of preoperative TACE for HCC remain a matter of debate.

The aim of the present study was to evaluate the influence of preoperative TACE on survival after SR for HCC.

Patients and methods

Patients. SR was performed in 342 treatment-naïve HCC patients at the Department of Surgery, Osaka Red Cross Hospital, Japan, between January 2004 and June 2012. Of these, we excluded patients operated on without curative intent.
(n=41), with surgery-related death (n=3), with TACE alone before surgery (n=10), and with transcatheter arterial lipiodol chemolization alone before surgery (n=53). We defined curative surgery as the resection of all tumors detectable using imaging modalities. A total of 235 HCC patients who underwent SR were therefore analyzed in the present study (Fig. 1), including 110 patients who underwent TACE before surgery (TACE group) and 125 patients who did not (control group). All patients in the TACE group received one session of TACE, and patients in the control group received angiography alone. The decision to perform TACE prior to surgery was made mainly by the attending physician. Written informed consent was obtained from all patients prior to TACE and surgery, and the study protocol complied with all of the provisions of the Declaration of Helsinki. The present study comprised a retrospective analysis of patient records, and all treatments were conducted in an open-label manner.

**HCC diagnosis and stage.** HCC was diagnosed using abdominal ultrasound and dynamic computed tomography (CT) scans (hyperattenuation during the arterial phase in all or some part of the tumor and hypoattenuation in the portal-venous phase) and/or magnetic resonance imaging (MRI), based mainly on the recommendations of the American Association for the Study of Liver Diseases (9). Arterial and portal phase dynamic CT images were obtained at ~30 and 120 sec, respectively, after the injection of the contrast material. Abdominal angiography combined with CT assistance was performed on all patients before SR, in line with the recommendations of Yamasaki et al, who reported that this technique was useful for detecting small satellite nodules (14). HCC stage was determined using the Liver Cancer Study Group of Japan (LCSGJ) staging system (15). HCC was confirmed pathologically in resected specimens at surgery, except for cases with complete necrosis.

**TACE procedure.** TACE was performed in accordance with Japanese guidelines (16), and consisted of catheterization via the femoral artery with super-selective cannulation to the hepatic artery feeding the target HCC. An emulsion containing Farmorubicin (epirubicin hydrochloride; Pfizer), mitomycin C (Kyowa Hakko Kirin Co. Ltd., Tokyo, Japan) and lipiodol (iodine addition products of ethyl esters of fatty acids obtained from poppy seed oil; Mitsui, Japan) was infused via the femoral artery with super-selective cannulation to provide a clear vascular map of the liver anatomy. The Cavitron Ultrasonic Aspiration system (CUSA; Valley Lab Corp., Boulder, CO, USA) was used to dissect the liver tissue. Hemostasis was achieved by dipolar electric coagulation and suturing. The Pringle maneuver was usually used in cases with cirrhotic liver, with a clamp/unclamp time of 15/5 min policy.

**Laparoscopic hepatectomy was performed using the four-trocar technique.** The first trocar was placed by a small incision below the umbilicus for pneumoperitoneum creation. The tumor extent and its relationship with the vascular anatomy and other tumors in the liver were explored usingIOUS. The Pringle maneuver was usually used in cases with cirrhotic liver, with a clamp/unclamp time of 15/5 min policy.

**Follow-up.** Follow-up consisted of periodic blood tests and monitoring of tumor markers, including α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), measured using a chemiluminescent enzyme immunoassay (Lumipulse PIVKAII Eisai, Eisai, Tokyo, Japan). Dynamic CT scans and/or MRI were obtained every 3-4 months after SR. Chest CT, whole abdominal CT and bone scintigraphy were performed when extrahepatic HCC recurrences were suspected.
Statistical analysis. The primary endpoints were overall survival (OS) and recurrence-free survival (RFS), and the secondary endpoints were procedure-related complications. Data were analyzed using univariate and multivariate analyses. Continuous variables were compared using unpaired t-tests and categorical variables were compared using Fisher’s exact tests. Time to recurrence was defined as the interval between surgery and first confirmed recurrence. For analysis of RFS, follow-up ended at the time of first recurrence; other patients were censored at their last follow-up visit or the time of death from any cause without recurrence. For analysis of OS, follow-up ended at the time of death from any cause, and the remaining patients were censored at the last follow-up visit. The Cox proportional hazards model was used for multivariate analysis of factors that were considered significant in univariate analysis. These statistical methods were used to estimate the interval from surgery. Data were analyzed using SPSS software, version 9.0 (SPSS Inc., Chicago, IL, USA) for Microsoft Windows. Data are expressed as means ± standard deviation. Values of P<0.05 were considered to be statistically significant.

Results

Patients. Baseline characteristics of the TACE and control groups are shown in Table I. The mean observation periods were 2.8±1.8 years in the TACE group and 2.9±2.1 years in the control group. There were significant differences between the two groups in terms of HCC stage, tumor number and pretreatment DCP-value, indicating that patients in the TACE group had more advanced tumor characteristics. Anatomical resection was performed in 54 patients in the TACE group, and non-anatomical resection in 56 patients in the control group (P=0.603).

Histological findings. The histological findings in the TACE and control groups are shown in Table II. Complete necrosis occurred in 21 patients (19.1%) in the TACE group. Microscopic vascular invasion was found in 32 patients (29.1%) in the TACE group and 47 patients (37.6%) in the control group.

Cumulative OS and RFS in the TACE and control groups. The 1-, 3- and 5-year OS rates in the two groups were 87.4, 76.0 and 62.5%, respectively, in the TACE group and 94.9, 79.0 and 57.8%, respectively, in the control group (Fig. 2). RFS was higher in the TACE group, but the difference was not significant (P=0.062).

OS and RFS in TACE responders and non-responders. In terms of the efficacy of TACE, 21 patients were classified as TE4, 64 as TE3, 25 as TE2 and 0 as TE1. The TACE group was further categorized into TACE responders (TE4 and TE3; n=85) and TACE non-responders (TE2 and TE1; n=25), and OS and RFS were compared between the TACE responders, TACE non-responders, and the control group. There were significant differences in OS between the three groups (TACE responders vs. controls, P=0.381; controls vs. TACE non-responders,
Factors contributing to OS after SR. Univariate analysis identified pretreatment therapy (P<0.001), HCC stage (P=0.012), maximum tumor size ≥4 cm (P=0.003), tumor number (P=0.005), total bilirubin ≥1 mg/dl (P=0.003), serum albumin ≥4.0 g/dl (P=0.013), AFP ≥100 ng/ml (P<0.001), DCP ≥100 mAU/ml (P=0.020) and microscopic vascular invasion (P=0.002) as significant factors contributing to OS after SR (Table III). Multivariate analysis of the nine factors found to be significant in univariate analysis further identified pretreatment therapy (TACE responder, P=0.018), pretreatment therapy (TACE non-responder, P=0.019), total bilirubin ≥1 mg/dl (P=0.003), serum albumin ≥4.0 g/dl (P=0.001), AFP ≥100 ng/ml (P=0.011) and microscopic vascular invasion (P=0.021) as significant contributors to OS. The hazard ratios (HRs) and 95% confidence intervals (CIs) for these factors are detailed in Table IV.

Factors contributing to RFS after SR. Univariate analysis identified pretreatment therapy (P=0.004), HCC stage (P<0.001), maximum tumor size ≥4 cm (P=0.049), tumor
Figure 4. Overall survival (OS) in the transcatheter arterial chemoembolization (TACE) responder group (n=85), the TACE non-responder group (n=25) and the control group. There were significant differences between the three groups in terms of OS (TACE responders vs. controls, P=0.381; controls vs. TACE non-responders, P<0.001; TACE responders vs. TACE non-responders, P<0.001; overall significance, P<0.001; log rank test).

Table III. Univariate analyses contributing to OS and RFS after surgical resection (n=235).

<table>
<thead>
<tr>
<th>Variables</th>
<th>n</th>
<th>OS P-value</th>
<th>RFS P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥70 (yes/no)</td>
<td>119/116</td>
<td>0.229</td>
<td>0.794</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td>179/56</td>
<td>0.504</td>
<td>0.848</td>
</tr>
<tr>
<td>Pretreatment therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TACE-R/TACE-NR/controls</td>
<td>85/25/125</td>
<td>&lt;0.001</td>
<td>0.004</td>
</tr>
<tr>
<td>Cause of liver disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B/hepatitis C/non-B/non-C</td>
<td>30/137/68</td>
<td>0.713</td>
<td>0.935</td>
</tr>
<tr>
<td>HCC stage (I, II/III, IV)</td>
<td>155/80</td>
<td>0.012</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Maximum tumor size ≥4 cm (yes/no)</td>
<td>115/120</td>
<td>0.003</td>
<td>0.049</td>
</tr>
<tr>
<td>Tumor number (single/multiple)</td>
<td>159/76</td>
<td>0.005</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ICGR 15 ≥12%</td>
<td>113/122</td>
<td>0.289</td>
<td>0.319</td>
</tr>
<tr>
<td>Total bilirubin ≥1.0 mg/dl (yes/no)</td>
<td>62/173</td>
<td>0.003</td>
<td>0.041</td>
</tr>
<tr>
<td>Serum albumin ≥4.0 g/dl (yes/no)</td>
<td>125/110</td>
<td>0.013</td>
<td>0.231</td>
</tr>
<tr>
<td>AST ≥50 IU/l (yes/no)</td>
<td>106/129</td>
<td>0.353</td>
<td>0.005</td>
</tr>
<tr>
<td>ALT ≥50 IU/l (yes/no)</td>
<td>90/145</td>
<td>0.263</td>
<td>0.012</td>
</tr>
<tr>
<td>Platelets ≥10×10^4/mm^3 (yes/no)</td>
<td>172/63</td>
<td>0.502</td>
<td>0.549</td>
</tr>
<tr>
<td>Prothrombin time ≥80% (yes/no)</td>
<td>177/58</td>
<td>0.112</td>
<td>0.144</td>
</tr>
<tr>
<td>AFP ≥100 ng/ml (yes/no)</td>
<td>70/165</td>
<td>&lt;0.001</td>
<td>0.036</td>
</tr>
<tr>
<td>DCP ≥100 mAU/ml (yes/no)</td>
<td>151/84</td>
<td>0.020</td>
<td>0.180</td>
</tr>
<tr>
<td>Microscopic capsule (yes/no)</td>
<td>185/50</td>
<td>0.696</td>
<td>0.171</td>
</tr>
<tr>
<td>Microscopic capsule invasion (yes/no)</td>
<td>133/102</td>
<td>0.147</td>
<td>0.520</td>
</tr>
<tr>
<td>Microscopic vascular invasion (yes/no)</td>
<td>80/155</td>
<td>0.002</td>
<td>0.021</td>
</tr>
<tr>
<td>Microscopic surgical margin (yes/no)</td>
<td>64/171</td>
<td>0.818</td>
<td>0.951</td>
</tr>
</tbody>
</table>

OS, overall survival; RFS, recurrence-free survival; TACE-R, TACE responders; TACE-NR, TACE non-responders; HCC, hepatocellular carcinoma; ICGR 15, indocyanine green retention at 15 min; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, α-fetoprotein; DCP, des-γ-carboxy prothrombin. *log-rank test.

Figure 5. Recurrence-free survival (RFS) in the transcatheter arterial chemoembolization (TACE) responder group (n=85), the TACE non-responder group (n=25) and the control group. There were significant differences between the three groups in terms of RFS (TACE responders vs. controls, P=0.006; controls vs. TACE non-responders, P=0.190; TACE responders vs. TACE non-responders, P=0.004; overall significance, P=0.004).
number (P<0.001), total bilirubin ≥1 mg/dl (P=0.041), aspartate aminotransferase ≥50 IU/l (P=0.005), alanine aminotransferase ≥50 IU/l (P=0.012), AFP ≥100 ng/ml (P=0.036) and microscopic vascular invasion (P=0.021) as significant factors contributing to RFS after SR (Table III). Multivariate analysis of the nine factors found to be significant in univariate analysis confirmed pretreatment therapy (TACE non-responder, P=0.039), tumor number (P=0.038) and AFP ≥100 ng/ml (P=0.043) as significant contributors to RFS. The HRs and 95% CIs for these factors are detailed in Table V.

Comparison of baseline characteristics between TACE responders and non-responders. The baseline characteristics of the TACE responders (n=85) and non-responders (n=25) are shown in Table VI. There were significant differences between the groups in terms of HCC stage, maximum tumor size, pretreatment AFP value and pretreatment DCP value, indicating that TACE non-responders had more advanced tumor characteristics than TACE responders.

Causes of death. Twenty-nine patients in the TACE group (26.4%) died during the follow-up period. The causes of death were HCC recurrence in 21 patients, liver failure in 6 patients and other causes in 2 patients. Thirty-two patients in the control group (25.6%) died during the follow-up period, and the causes of death were HCC recurrence in 21 patients, liver failure in 7 patients and other causes in 4 patients.

HCC recurrence in the TACE and control groups. Fifty-three patients in the TACE group (48.2%) and 69 (55.2%) in
the control group had HCC recurrence during the follow-up period. The patterns of HCC recurrence after SR in the TACE group were as follows: single HCC recurrence in the liver in 12 patients; multiple HCC recurrences in the liver in 29 patients; multiple HCC recurrences in the liver with lung metastases in 7 patients; multiple HCC recurrences in the liver with brain metastases in 1 patient; and multiple HCC recurrences in the liver with multiple lymph node (LN) metastases in 4 patients. The patterns of HCC recurrence after SR in the control group were: single HCC recurrence in the liver in 32 patients; single HCC recurrence with invasion of the right hepatic vein in 1 patient; multiple HCC recurrences in the liver in 33 patients; multiple HCC recurrences in the liver with LN metastases in 1 patient; multiple HCC recurrences in the liver with portal vein invasion in 1 patient; and multiple HCC recurrences in the liver with lung metastases in 1 patient.

The treatment methods for the first HCC recurrence in the TACE group were SR in 2 patients, radiofrequency ablation (RFA) in 23 patients, TACE in 16 patients, percutaneous ethanol injection (PEI) in 2 patients, systemic chemotherapy in 7 patients and no specific treatment in 3 patients. The treatment methods used in the control group were SR in 6 patients, RFA in 36 patients, TACE in 15 patients, PEI in 2 patients, systemic chemotherapy in 4 patients and no specific treatment in 6 patients.

Operation time, surgical blood loss and hospitalization period in the TACE and control groups. The mean operation times were 259.5±74.5 min in the TACE group and 269.1±87.8 min in the control group (P=0.881). The mean surgical blood loss was 764.1±713.5 ml in the TACE group and 874.2±886.8 ml in the control group (P=0.334). The mean periods from surgery until discharge were 17.9±15.8 days in the TACE group and 16.6±10.4 days in the control group (P=0.447) (Table II).

TACE and surgery-related serious adverse events (SAEs). The interval from TACE until surgery in the TACE group was 38.0±17.6 days, and no patient was prevented from undergoing SR as a result of TACE-related complications. Surgery-related SAEs in the TACE group included abscess formation in 5 patients, bile leakage in 4 patients, refractory ascites in 2 patients, aspiration pneumonia in 2 patients, gastrointestinal bleeding in 2 patients, acute heart failure in 1 patient and perforation of the small intestine in 1 patient. Equivalent complications in the control group included abscess formation in 3 patients, bile leakage in 4 patients, refractory ascites in 6 patients, aspiration pneumonia in 2 patients, acute respiratory distress syndrome in 1 patient and brain infarction in 1 patient. All these SAEs improved during the same hospitalization. There was no significant difference between the groups in terms of SAEs related to surgery (P=0.714).

Subgroup analyses of OS and RFS in patients with HCC stage I or II. TACE non-responders had more advanced tumor characteristics than TACE responders, and we therefore performed subgroup analyses in patients with HCC stage I or II (n=155) and HCC stage III or IV (n=80). Patients with HCC stage I or II comprised 52 TACE responders, 10 TACE non-responders and 93 controls. Although the TACE non-responders had a poorer prognosis in terms of OS, there was no overall significant difference between the three groups (TACE responders vs. controls, P=0.523; controls vs. TACE responders vs. TACE non-responders, P=0.004).
non-responders, P=0.118; TACE responders vs. TACE non-responders, P=0.040; overall significance, P=0.148) (Fig. 6). However, there were significant differences between the three groups in terms of RFS (TACE responders vs. controls, P=0.003; controls vs. TACE non-responders, P=0.992; TACE responders vs. TACE non-responders, P=0.105; overall significance, P=0.013; log rank test).

Subgroup analyses of OS and RFS in patients with HCC stage III or IV. The patients with HCC stage III or IV (n=80) included 33 TACE responders, 15 TACE non-responders and 32 controls. There were significant differences in OS between the three groups (TACE responders vs. controls, P=0.267; controls vs. TACE non-responders, P=0.025; TACE responders vs. TACE non-responders, P=0.010; overall significance, P=0.011; log rank test).

Discussion
To the best of our knowledge, the present study represents one of the largest comparative studies on the influence of preop-
operative TACE on the survival of patients with resectable HCC (3,10,12,13,19-21). Although four randomized controlled trials have investigated the effects of pretreatment TACE on survival after SR (3,10,12,13) and similarly concluded that pretreatment with TACE did not improve survival after SR, the sample sizes, TACE procedures and baseline clinical characteristics differed among these studies. Hence, the efficacy of pretreatment TACE on survival after SR remains unclear.

In this study, multivariate analysis identified TACE responder and TACE non-responder in terms of OS, and TACE non-responder in terms of RFS, as significant independent prognostic factors after SR. Moreover, in terms of RFS in stage I or II HCC patients and OS in stage III or IV HCC patients, the overall differences reached significance in univariate analysis. These results suggest that the therapeutic efficacy of pretreatment TACE is associated with clinical outcome after SR.

The extent of tumor vascularization is significantly associated with the degree of TACE efficacy, and a high degree of vascularization is thus considered to be a predictive sign for response to TACE (22). Preoperative TACE may thus be recommended in HCC patients with a high degree of tumor vascularity (23), although Adachi et al reported that preoperative TACE should be avoided as incomplete tumor necrosis promotes the hematogenous spread of residual tumor cells during SR (24).

Several studies have reported that serum vascular endothelial growth factor (VEGF) can act as a prognostic factor for the treatment of HCC (25-27). Sergio et al (22) also demonstrated that when TACE for HCC was ineffective, it might induce a significant increase in serum VEGF levels and affect patient survival. TACE non-responders in the present study may thus have had a poor prognosis associated with increased serum VEGF levels. It has also been suggested that preoperative TACE should not be performed in patients with a low degree of vascularization. Further studies are needed to clarify this issue.

In terms of tumor histology, the current study included 13 patients (52.0%) with poorly differentiated HCC in the TACE non-responder group and 22 patients (25.9%) with poorly differentiated HCC in the TACE responder group (P=0.017). Patients with poorly differentiated HCC would be expected to have a poorer prognosis because of their poor response to TACE.

Liver function parameters reflected by serum bilirubin and serum albumin were significant independent factors linked to OS in the present study. Several studies have investigated the importance of maintaining liver function on survival after surgery for HCC (28,29). Our results were consistent with previous reports; in HCC patients with poor liver function, branched chain amino acid therapy to maintain liver function may be effective to optimize the clinical outcomes (7).

High pretreatment AFP level was an independent prognostic factor in terms of both OS and RFS in our study. HCC patients with high AFP levels had poorer tumor histology and larger tumor mass (30), which may be associated with their poorer clinical outcome. Microvascular invasion was a significant prognostic factor in univariate and multivariate analyses in terms of OS, and in the univariate analysis in terms of RFS. Lim et al reported that microvascular invasion was an adverse predictor of OS and RFS following SR for HCC (31). Our results were in agreement with their reports. Careful monitoring for HCC recurrence will thus be needed in patients with microvascular invasion, and patients with high pretreatment AFP levels.

Zhou et al reported that several patients in their randomized controlled trial could not undergo definitive surgery because of tumor progression after TACE or because of TACE-related SAEs. However, no patients in the current study were unable to undergo surgery (3). Moreover, there were no significant differences between the TACE and control groups in terms of operation time, blood loss during surgery and hospitalization period. Our study results, therefore, suggest that the TACE procedure was safe in patients with resectable HCC.

The present study has several limitations. First, it is a retrospective study. Second, the follow-up period was relatively short for survival analysis. Third, the sample sizes of the TACE responder, TACE non-responder, and control groups were not balanced. However, despite these limitations, the results of this study demonstrated that the therapeutic efficacy of preoperative TACE may be associated with clinical outcome after SR in patients with HCC. Preoperative TACE may thus be a prognostic factor in patients with resectable HCC after SR.

Acknowledgements

The authors would like to thank all the staff in the angiography room and the operation room of the Osaka Red Cross Hospital for their valuable support.

References


